|Awarded On||December 05, 2012|
|Title||Clinical Application of Umbilical Cord Blood-Derived Designer T Cells|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Laurence Cooper|
|Cancer Sites||Leukemia, Lymphoma|
Many leukemias and lymphomas arise from the cancerous transformation of B cells and patients with advanced disease may be successfully treated by umbilical cord blood transplantation (UCBT). This is a lifesaving procedure that infuses umbilical cord blood (UCB) after high dose chemotherapy and sometimes radiotherapy to restore the ability of the recipient to generate white blood cells (immune cells), red blood cells, and platelets. The engrafted immune system can recognize leukemia and lymphoma cells resulting in the cure of some patients. However, patients with aggressive leukemias and lymphomas still have a poor survival due to relapse of their tumor and we seek to improve their outcome by...